Crossmark

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

Crossref DOI link: https://doi.org/10.1186/s12890-025-03500-8

Published Online: 2025-01-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sader, Helio S.

Mendes, Rodrigo E.

Ryan Arends, S. J.

Doyle, Timothy B.

Castanheira, Mariana
Funding

Funding for this research was provided by:

AbbVie (22-ALG-04 M3)
License Information

Text and Data Mining valid from 2025-01-24

Version of Record valid from 2025-01-24
More Information

Article History

Received: 4 April 2024

Accepted: 13 January 2025

First Online: 24 January 2025

Declarations

:

: This study does not include factors necessitating patient consent. The study used bacterial isolates stored by clinical laboratories and the participant laboratories did not provide patient identification.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below